Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 10.025 1,000 07:42:59
Bid Price Offer Price High Price Low Price Open Price
9.80 10.25 10.025 10.025 10.025
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.35 -6.33 -1.50 43
Last Trade Time Trade Type Trade Size Trade Price Currency
08:00:25 O 1,000 9.93 GBX

Kromek (KMK) Latest News

More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
20/6/202219:11Kromek Group PLC6,239
05/1/202209:19Kromek Group (KMK) - Overvalued AIM mugging182

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:00:269.931,00099.30O
2022-06-27 15:26:3510.1712,5001,271.25O
2022-06-27 15:11:3610.0273,4247,357.08O
2022-06-27 14:23:5510.026,101611.32O
2022-06-27 14:21:0610.17100,00010,170.00O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
28/6/2022
09:20
Kromek Daily Update: Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 10.03p.
Kromek Group Plc has a 4 week average price of 9.75p and a 12 week average price of 7.95p.
The 1 year high share price is 21.25p while the 1 year low share price is currently 7.95p.
There are currently 431,851,820 shares in issue and the average daily traded volume is 238,578 shares. The market capitalisation of Kromek Group Plc is £43,293,144.96.
16/5/2022
11:24
charlie_bucket: I believe cash of £5.1m mentioned is gross cash. Net cash after deducting borrowings will be lower, maybe even negative. Borrowings were £6.8m in the interims, and cash was £10.2m. Does look to me like shareholder money is being spent on research papers in getting that share price up so that they can get shares away without being hugely diluting. And with no directors using their own money to buy shares to try and have the same effect. Say they want to raise £15m plus fees. Current market cap is £35m at price of 8 pence. That’s 200 million new shares, nearly half as many as now in issue! I think existing and new shareholders need to be careful. Despite the technology and products’ potential and the progress being made, I believe this can still go down further and even to zero if they can’t raise more equity capital particularly if the overall market has a sharp downturn. Ask yourself: are the same institutions who bought in at 15 pence last time going to double down and buy more at a lower share price when they are holding a loss in these market conditions? Has what the company said last time come true? Or are the institutions going to invest elsewhere? Another point is that I believe a “clean” audit report for the year end accounts without a “going concern” qualification would depend on new equity funding being in place to guarantee trading for the 12 months after the issue of the annual accounts later this year. All just my opinions, need to do your own research and come to your own.
14/2/2022
12:19
ark87: KMK share price also looks to be entering very dangerous times.
27/1/2022
14:24
charlie_bucket: As a counterweight to the optimism from AQC888 and others: A concern of mine is that the company is looking for a short term boost to the share price before announcing a placing / cash raise again soon. Particularly helpful if the share price rises on the back of another Simon Thompson recommendation. This is still very much a loss making company which will need future cash raises – despite talk of “cash profit” or “Adjusted EBITDA” – since revenue isn’t high enough yet to break even, plus development costs go to the balance sheet and don’t get deducted until later in the P&L. For last 6 months just published, loss before tax was £3.1m but that’s after forgiveness of COVID loans (£1.3m) and £3.1m of R&D costs capitalized which was higher than the R&D cost amortization (£1.0m). If my thinking here is correct, that makes £6.5m underlying cash outflow (excl. tax) for a half year. They had cash balance of £10.2m end of October minus £4.8m short term borrowings, so £5.4m net cash. Timing of placing announcement last year was 12th February, and share price fell about 15% on day of announcement. Now could be the time of year that they think about another one.
13/1/2022
17:00
ark87: I'm surprised there is not more excitement/volume here. According to ACQ we have a 35% chance of going "stratospheric" and 35% chance of seeing "only" 28p in coming weeks. That's a 70% chance of massive gains. "1)A government order has been received and they are continuing discussions with multiple other governments. Kromeks share price goes stratospheric, hit the headlines and see share price go beyond 80p within a week. It would eclipse the rest of the business. My assessment of this is a 35% chance. 2)Kromeks main business is slightly ahead of analysts forecasts and they are close to finalising deals with the biological pathogen detector. Even though we all know this to be the case already, as the ceo has already said this. When it’s announced with the interim results it’s likely to cause some excitement and share price will get close to 28p. My assessment of this is 35%."
08/1/2022
10:28
aqc888: Sentiment has clearly changed quite dramatically with Kromek looking at the share price over the last 2years, including my sentiment. My last post over on LSE points out the many conflicting views of Kromek that are interesting to navigate through. In fact I just said that gains were frothy and hard not to sell when the share price booms over on lse. The only thing that doesn’t change is Quepassas refusal to state his interest in Kromek and his DELIBERATE attempts to cause panic as seen in other posts of his (won’t repeat his nonsense that was disproved comprehensively by multiple other posters). I think people can judge for themselves who can and can’t be trusted. I’ve openly discussed my frustrations with Kromek and had my views change over time. Quepassa has a very unusual position on Kromek, he puts in a lot of time and effort trying to discredit a company he apparently has no interest in. I’ve built up a large holding in Kromek, that’s my interest here. What’s your interest QP? You spend a lot of your time going through company accounts, old posts etc trying to find things to ‘warn’ others about, warning how the share price is about to tank and dire etc etc. Is this a public service/charity you’re operating? Or would you like to enlighten us to your noble views? I suspect I know your predictable answer - yawn yawn yawn.
04/1/2022
19:55
aqc888: Two weeks today we’ll have the interim results. Here are my predictions: 1)A government order has been received and they are continuing discussions with multiple other governments. Kromeks share price goes stratospheric, hit the headlines and see share price go beyond 80p within a week. It would eclipse the rest of the business. My assessment of this is a 35% chance. 2)Kromeks main business is slightly ahead of analysts forecasts and they are close to finalising deals with the biological pathogen detector. Even though we all know this to be the case already, as the ceo has already said this. When it’s announced with the interim results it’s likely to cause some excitement and share price will get close to 28p. My assessment of this is 35%. However, importantly in this scenario the Simon Thompson card will be played 3weeks later. I think this scenario will almost certainly mean Kromek will be included in his much awaited bargain shares edition which will see it surge from under 30p to nearing 50p. 3)Kromeks main business is slightly ahead of forecasts and very vague news about the biological pathogen detector. 15% chance. Share price will move marginally up or down. 4)Kromeks main business is more or less in line with forecasts and slightly negative news on biological pathogen detector. 10% chance. Share price back down to 13-15p. 5)Kromeks main business underperforming and no news of biological pathogen detector. 5% chance. Share price down to 10-12p. Wildcards - they’ve received bids for part of all of business. 5% chance. Share price up to 50p A lot of upside here in my opinion. Looking forward to the results... Not far off reaching highs of 18p before interim results from last forecast when share price was 14.5p...
01/1/2022
11:44
aqc888: Ark87, the bar being set so low is what makes Kromek such a bargain in my opinion. If you look at news reports in the core markets of CZT scanners and nuclear detectors, these markets are set to have strong growth in the previous and coming years. This should see Kromek beating market expectations on the 18th jan. Kromek currently has a bad relationship with the market given previous underachievements, even their ‘upto £17m’ RNS caused the share price to fall. I believe if the board give a positive update on the biological pathogen detector on the 18th jan, even if it’s without a solid order yet, the news will likely be taken more seriously by the market if Kromeks overachieving and beating analysts forecasts in the rest of the business. I think it’s 50:50 whether there will be a positive update on a government sale of the detector yet, but given the wave of omicron I think the chances of this happening have increased. A bonus of Simon Thompson covering Kromek and repeatedly giving it a rare ‘strong buy’ is that if the share price doesn’t react strongly enough on 18th jan, as is often the case with Kromek, we have the extremely strong prospect, in my opinion, of Simon Thompson including it in his early feb bargain shares edition given the lower risk and higher rewards Kromek will offer than in the past. It should report that it’s entered profitability on jan 18th and has the biological pathogen detector deals with governments imminent. Any momentum started on the 18th jan will be added to by Simon Thompson in early Feb. I can see a dramatic turnaround in Kromeks share price in the coming 6 weeks and genuinely believe it has the prospect of going well over £1 by the end of 2022 given the potential size of just one government order for the biological pathogen detector. Let alone orders from the multiple governments the ceo stated they were in serious talks with.
20/12/2021
19:25
aqc888: Boomboy, you need to wait for the interim results and news of the biological pathogen detector. All the ups and downs upto that point will be overturned by these results. I’m still confident Kromek will be included in Simon Thompson’s small cap bargain shares in the early feb edition. If he thought it was a strong buy 6-12months ago then right now there is positive news coming in all directions and segments, it will gain anything from 20-40% on the day if it’s included. Forget the share price, look at the business and each segment, to recap; Nuclear detectors Kromek should be a beneficiary of the UK Government’s £329m five-year nuclear detection budget, given that Kromek’s product offering covers key areas of border control and terrorism threat detection – its dirty bomb detectors are now deployed in 26 countries – and the UK Government is “localising supply chains.” Basu revealed that Kromek has £20m worth of revenue in active procurement in the nuclear sector that “could be delivered this year”, highlighting the marked increase in activity being seen across major international markets. CZT scanners; They had that ‘upto’ £17m contract. Plus news reports show hospitals delayed scanner replacement during pandemic and a strong market was forecast here. There’s also the new breast cancer scanners and baggage / industrial use new orders. Biological pathogen detector; We all know about this positive news on the horizon... 2022 seems like the year it’s all going to come together. Will be a good inclusion in Simon Thompson’s February edition and hopefully perform as well as similar IP heavy, share price weak, company Xaar last year. Which went from 42p (in his feb 2020 list) to highs of 240 or 169p today. Kromek reaching highs of 60-80p in the next few years wouldn’t be so extraordinary. After all a share price at that level could still be seen as a bargain considering the price of rival CZT scanner company to Canon last year - plus all the other segments of Kromek. Things have the potential to turn around very dramatically here. I’m increasingly confident.
05/12/2021
07:32
charlie_bucket: If you own shares in Kromek as I see it you've bought a lottery ticket (bio-security) on top of a regular investment (nuclear, medical). For bio-security, think in probabilities. First order sizes could be very big. Very big number times % probability still equals big number. That's how to value the impact on the shares. Just because they haven't announced any sales of bio-security products yet doesn't mean they are failing, but says that they're still working on making those lottery numbers come up. You can question whether the CEO is the right man for all this commercially, I share the same concerns. I think that’s already factored into the current share price. Clearly he's technically strong which is good because if these products don't work then you're not selling any at all. If he gets enough advice and door-opening from others (chairman, bought-in consultants) then that can compensate. And yes, loss-making businesses do need to raise more funds sometime in the future, that just goes with the territory. If shareholders think the share price is good value vs the future profit potential, then they'll pay up and on we go. In the meantime you have an established and growing business with strong products and growth in the other areas (nuclear, medical) that might even justify the current share price on their own and give protection to share price on downside.
22/10/2021
17:33
b00mb0y: “Status Quo” down down deeper and down. KMK share price “ down down deeper and down. Status quo- the current state of affairs
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220628 07:29:08